Assessment of NETest Clinical Utility in a U.S. Registry-Based Study.

摘要: BACKGROUND The clinical relevance of molecular biomarkers in oncology management has been recognized breast and lung cancers. We evaluated a blood-based multigene assay for neuroendocrine tumors (NETs) real-world study (U.S. registry NCT02270567). Diagnostic accuracy relationship to disease status two cohorts (treated watch-and-wait) were evaluated. MATERIALS AND METHODS Patients with NETs (n = 100) followed 6-12 months. Patients' primary gastroenteropancreatic (68%), 20%, unknown origin (12%). Characteristics included well-differentiated, low-grade (97%), stage IV (96%); treatment surgery (70%); drug (56%). NETest was measured at each visit determined by RECIST. Scores categorized as low (NETest 14%-40%) or high (≥80%) defined stable progressive. Multivariate analyses the strength association progression-free survival (PFS). RESULTS diagnostic 96% concordant (95%) image-demonstrable disease. reproducible (97%) (98%). only feature linked PFS (odds ratio, 6.1; p 95%) It is >90% effective guiding decisions conjunction imaging. Monitoring watch-and-wait groups. Low levels supported no change reduced need High indicated intervention. Real-time liquid biopsy assessment utility can contribute additional value patient strategies outcomes.